Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer

被引：71
|
作者：
Haunschild, Carolyn E. [1 ,2 ]
Tewari, Krishnansu S. [2 ,3 ]
机构：
[1] Univ Calif Irvine, Dept Obstet & Gynecol, 333 City Blvd West,Suite 1400, Orange, CA 92868 USA
[2] Univ Calif Irvine, Div Gynecol Oncol, 333 City Blvd West,Suite 1400, Orange, CA 92868 USA
[3] Univ Calif Irvine, Dept Obstet Gynecol, City Tower,333 City Blvd,West Suite 1400, Orange, CA 92868 USA
来源：
FUTURE ONCOLOGY | 2020年 / 16卷 / 07期
关键词：
bevacizumab; biological therapy; clinical trials; gynecologic; ovarian; GYNECOLOGIC-ONCOLOGY-GROUP; PHASE-III TRIAL; PEGYLATED LIPOSOMAL DOXORUBICIN; ADVANCED EPITHELIAL OVARIAN; INTERVAL DEBULKING SURGERY; PRIMARY PERITONEAL; OPEN-LABEL; FALLOPIAN-TUBE; INTRAPERITONEAL CISPLATIN; NEOADJUVANT CHEMOTHERAPY;
D O I：
10.2217/fon-2019-0042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
On 13 June 2018, Genentech, Inc. issued a press release announcing that the US FDA had approved the antiangiogenesis drug, bevacizumab, in combination with chemotherapy for frontline and maintenance therapy for women with newly diagnosed ovarian cancer. Regulatory approval was based on the National Cancer Institute-sponsored Gynecologic Oncology Group (GOG) protocol 0218, the Phase III, randomized, placebo-controlled, double-blind, multi-center and multi-national clinical trial that met its primary end point, progression-free survival. Bevacizumab is now approved in the frontline, platinum-sensitive recurrent and platinum-resistant recurrent settings for epithelial ovarian cancer. This review will address the broad range of clinical trials addressing the efficacy of bevacizumab use in ovarian cancer.
引用
收藏
页码：225 / 246
页数：22
相关论文
共 50 条
  • [31] Maintenance Therapy in the Treatment of Recurrent Epithelial Ovarian Cancer
    Gnade, Colette
    Mcdonald, Megan E.
    CLINICAL OBSTETRICS AND GYNECOLOGY, 2020, 63 (01): : 86 - 91
  • [32] FURTHER ANALYSES HIGHLIGHT BENEFITS OF PARP INHIBITORS AS FRONTLINE MAINTENANCE IN OVARIAN CANCER
    Wright, Kevin
    ONCOLOGY-NEW YORK, 2020, 34 (05): : 175 - 175
  • [33] Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
    Ray-Coquard, I.
    Pautier, P.
    Pignata, S.
    Perol, D.
    Gonzalez-Martin, A.
    Berger, R.
    Fujiwara, K.
    Vergote, I.
    Colombo, N.
    Maenpaa, J.
    Selle, F.
    Sehouli, J.
    Lorusso, D.
    Alia, E. M. Guerra
    Reinthaller, A.
    Nagao, S.
    Lefeuvre-Plesse, C.
    Canzler, U.
    Scambia, G.
    Lortholary, A.
    Marme, F.
    Combe, P.
    de Gregorio, N.
    Rodrigues, M.
    Buderath, P.
    Dubot, C.
    Burges, A.
    You, B.
    Pujade-Lauraine, E.
    Harter, P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25): : 2416 - 2428
  • [34] Shared decision making in frontline maintenance therapy for ovarian cancer: A qualitative assessment
    Haggerty, Ashley
    Barrett, Amy
    Dine, Jennifer
    Martin, Lainie
    Shah, Payal
    Buckingham, Trudy
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S286 - S286
  • [35] Maintenance Treatment with Bevacizumab Prolongs Survival in an In vivo Ovarian Cancer Model
    Mabuchi, Seiji
    Terai, Yoshito
    Morishige, Kenichiro
    Tanabe-Kimura, Akiko
    Sasaki, Hiroshi
    Kanemura, Masanori
    Tsunetoh, Satoshi
    Tanaka, Yoshimichi
    Sakata, Masahiro
    Burger, Robert A.
    Kimura, Tadashi
    Ohmichi, Masahide
    CLINICAL CANCER RESEARCH, 2008, 14 (23) : 7781 - 7789
  • [36] Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing
    Farolfi, Alberto
    Lorusso, Domenica
    Pignata, Sandro
    De Giorgi, Ugo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 172 - +
  • [37] EVALUATION OF REBOUND ASCITES FOLLOWING DISCONTINUATION OF BEVACIZUMAB IN RECURRENT OVARIAN CANCER
    O'Cearbhaill, R. E.
    Zhou, Q.
    Iasonos, A.
    Spriggs, D.
    Aghajanian, C.
    Sabbatini, P.
    ANNALS OF ONCOLOGY, 2010, 21 : 309 - 309
  • [38] The efficacy and toxicity of bevacizumab plus genicitabine in patients with recurrent ovarian cancer
    Bevis, K. S.
    Numnum, T. M.
    Shipman, K. A.
    Makhija, S.
    Barnes, M. N.
    Straughn, J.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S119 - S120
  • [39] Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer
    Musa, Fernanda
    Pothuri, Bhavana
    Blank, Stephanie V.
    Ling, Huichung T.
    Speyer, James L.
    Curtin, John
    Boyd, Leslie
    Li, Xiaochun
    Goldberg, Judith D.
    Muggia, Franco
    Tiersten, Amy
    GYNECOLOGIC ONCOLOGY, 2017, 144 (02) : 279 - 284
  • [40] CA125 response to bevacizumab in recurrent ovarian cancer.
    O'Cearbhaill, R. E.
    Zhou, Q.
    Iasonos, A.
    Diaz, J. P.
    Tew, W. P.
    Hensley, M. L.
    O'Flaherty, C.
    Aghajanian, C.
    Spriggs, D. R.
    Sabbatini, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345